New Haven, Connecticut-based Rallybio, a biopharmaceutical company, has closed $145 million in Series B funding. Pivotal bioVenture Partners led the round with participation from other investors that included TPG’s The Rise Fund, F-Prime Capital, funds managed by Tekla Capital Management LLC, Solasta Ventures, Fairview Capital, Mitsui & Co. Global Investment Inc, 5AM Ventures, Canaan Partners, New Leaf Venture Partners and Connecticut Innovations.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: